US panel rejects Avastin for breast cancer use
US panel rejects Avastin for breast cancer use
An expert panel on Wednesday urged the US Food and Drug Administration to strip the Roche-made drug Avastin of its label for use against breast cancer because it is neither safe nor effective.
Read more on AFP via Yahoo! News
Panel rejects Avastin for breast cancer
Panel rejects Avastin for breast cancer
An expert panel urged US Food and Drug Administration to strip drug Avastin of its use for breast cancer.
Read more on Sky News Australia
Biomarker panel identifies prostate cancer with 90 percent accuracy
Biomarker panel identifies prostate cancer with 90 percent accuracy
Researchers in England say they have discovered a set of biomarkers that can distinguish prostate cancer from benign prostate disease and healthy tissue with 90 percent accuracy. This preliminary data, if validated in larger ongoing studies, could be developed into a serum protein test that reduces the number of unnecessary biopsies and identifies men who need treatment before symptoms begin.
Read more on PhysOrg
Categories: Breast Cancer Screening Tags: accuracy, biomarker, cancer, identifies, Panel, percent, prostate
FDA panel supports Hologic’s 3-D device
FDA panel supports Hologic’s 3-D device
Hologic Inc.’s three-dimensional mammogram device is safe and improves breast-cancer detection when used in combination with conventional mammography, a US panel said. Hologic – Breast cancer – Mammography – Food and Drug Administration – Cancer
Read more on Boston Globe
Categories: Breast Cancer Mammogram Tags: Device, Hologic’s, Panel, SUPPORTS
Hologic Announces Panel Date For Its Selenia Dimensions (3-D) Digital Mammography Tomosynthesis System
Hologic Announces Panel Date For Its Selenia Dimensions (3-D) Digital Mammography Tomosynthesis System
Hologic, Inc. , a leading developer, manufacturer and supplier of premium diagnostics products, medical imaging systems and surgical products dedicated to serving the healthcare needs of women, today announced that the Company’s Selenia Dimensions three-dimensional digital mammography tomosynthesis system has been scheduled to be reviewed by the Radiological Devices Panel of the U.S.
Read more on PR Newswire via Yahoo! Finance
Categories: Breast Cancer Risks Tags: Announces, date, Digital, Dimensions, Hologic, mammography, Panel, Selenia, system, Tomosynthesis